CutisPharma Announces Launch Of FIRVANQ™ (vancomycin hydrochloride) For Oral Solution

Monday, April 2, 2018 Dental News
Email Print This Page Comment bookmark
Font : A-A+

Commercial availability of the only FDA-approved vancomycin oral liquid therapy replaces the need for a compounded oral liquid formulation of vancomycin

WILMINGTON, Mass., April 2, 2018 /PRNewswire/ -- CutisPharma announced today the commercial launch of FIRVANQ™ (vancomycin

hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

"We are pleased to announce that, effective today, FIRVANQ™ is commercially available to all pharmacies in the US," said Linda Carlino, Executive Director of Sales for CutisPharma. "FIRVANQ's availability means that pharmacists no longer need to compound oral vancomycin solution, which we expect will significantly expand accessibility of this important therapy to patients."

FIRVANQ™ has replaced CutisPharma's FIRST®-Vancomycin Unit-of-Use Compounding Kit, previously available to pharmacists who required an accurate, compliant way to compound vancomycin oral liquid therapy.  FIRVANQ™ is commercially available in 25 and 50 mg/mL strengths in convenient 150 mL and 300 mL sizes.   FIRVANQ™ is designed to be easy to use and has the potential to be a cost-effective alternative to existing vancomycin therapies.

About CutisPharma

CutisPharma, Inc., based in Wilmington, Mass., is a privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists.  CutisPharma's FIRST® Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. CutisPharma recently announced its acquisition by Novaquest Capital Management, L.L.C.  For more information, visit www.cutispharma.com, www.firvanq.com or contact us at media@cutispharma.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/cutispharma-announces-launch-of-firvanq-vancomycin-hydrochloride-for-oral-solution-300622593.html

SOURCE CutisPharma, Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store